PCSK9 and familial hypercholesterolemia: Congruently, pharmacological inhibition of PCSK9 with evolucumab reduced the increase in CIMT along the time in patients treated with statin [44] and improved the vascular functionality as determined by carotid stiffness in patients with familial hypercholesterolemia [45].